Reports & Analyses


Topic filters →
  • Accountability (5)
  • Marketisation (10)
  • NHS & Social Care Funding (6)
  • Patient safety in private hospitals (3)
  • Social care (4)
  • STPs (7)
  • Show All
Who decides the price and availability of NHS medicines? Outrage and dismay over the prices charged for new medicines are becoming an increasingly regular occurrence in England. Most recently it was over a life-extending drug for cystic fibrosis, Orkambi, with a hefty price tag of £105,000 per patient per year – far higher than NHS England’s counter offer of £500m over 5 years across all patients. The number of disputes between the... Read More

The financial assumptions underpinning the Government’s plans to close the NHS’s 30-billion-pound funding gap by 2020/21 are unrealistic and are likely to lead to a decline in the quality of and access to healthcare for patients. Subsequently there is a growing risk that that some vital services will collapse.

Read More

This analysis looks at the evidence showing that creating and maintaining markets in the NHS has incurred huge financial costs and significant ‘opportunity costs’ – money which could have spent upon patient care and clinical redesign. The analysis goes on to argue that it is possible for the NHS to offer patient choice and high-quality health-care without the market.

Read More

This analysis looks at the state of care for people with mental health problems today. It argues that the changes in the structure and scale of health services and benefits available to them has made treatment and recovery more difficult and that a changed cultural context has weakened society’s sense of obligation towards people with mental health problems.

Read More